PBGENE-DMD for Duchenne Muscular Dystrophy

This trial tests a new treatment called PBGENE-DMD, a gene therapy for boys with Duchenne Muscular Dystrophy (DMD), a condition that progressively weakens muscles due to a genetic defect. Researchers aim to determine if this treatment can safely and effectively correct the genetic issue in boys with specific mutations between exons 45 and 55 of the dystrophin gene. Eligible participants are boys with a confirmed DMD diagnosis, these specific mutations, and the ability to walk independently. The goal is to assess whether this one-time treatment can provide lasting benefits. As a Phase 1, Phase 2 trial, the research focuses on understanding the treatment's function in people and measuring its effectiveness in an initial, smaller group.

The trial requires that you stop using any products designed to increase dystrophin expression, including exon-skipping therapies, at least 6 months before starting and for at least 5 years after the gene therapy.

In early research, PBGENE-DMD showed promising results. Studies suggest it can significantly increase dystrophin protein levels in muscles, which is crucial for muscle strength. PBGENE-DMD also reduced CK levels, a marker of muscle damage, by 50-65%. This indicates the drug may help protect muscle tissue.

Unlike the standard treatments for Duchenne Muscular Dystrophy (DMD), which often include corticosteroids like prednisone and deflazacort to slow muscle degeneration, PBGENE-DMD uses a gene therapy approach. Researchers are excited because PBGENE-DMD targets the root cause of DMD by delivering a functional version of the dystrophin gene, which is defective in individuals with this condition. This innovative mechanism has the potential to significantly slow or even stop the progression of the disease, offering hope for a more effective and long-lasting treatment.

Research has shown that PBGENE-DMD, the investigational treatment studied in this trial, could be promising for Duchenne Muscular Dystrophy (DMD). In studies with mice, the treatment increased dystrophin protein levels, crucial for healthy muscles, by 3 to 12 times. Mice receiving PBGENE-DMD also exhibited muscles that were 66% stronger. Additionally, creatine kinase (CK) levels dropped by 50-65%, indicating less muscle damage. These results suggest that PBGENE-DMD might improve muscle health and outcomes for individuals with DMD.¹²⁵⁶⁷